The Unit 10 of Drug Formulation of the ICTS NANBIOSIS coordinated by the CIBER-BBN NanoBioCel group directed by Jose Luis Pedraz, which belongs to the University of the Basque Country, has been present at the signing of the agreement that gives support by the Provincial Council of Alava within the framework of the Advance Pharma Development project, together with the research and technological development center TECNALIA.
With this agreement, the NanoBioCel research group will receive in the next two years (2021-2023) a contribution of 650,000 €, which will allow the hiring of research personnel and the purchase of specific equipment for the regenerative medicine research line. The first equipment purchased to strengthen U10 in Bio-printing is the RegenHU Bioprinter: R-GEN 100, which will be located in the P3 Laboratory of the Lascaray Research Building. This bioprinter will bring two new technologies to the bioprinting techniques currently being used at U10: extrusion and droplet techniques. With RegenHU it will be possible to work with two new bioprinting processes: electrospinning and electrowriting. Electrospinning is a promising technique for the controlled release of drugs and electrowriting (electrostatic writing) will allow the construction of scaffolds with variable diameters in their design and elaboration.
